Inventor · disambiguated record
Lianshan Zhang
Also filed as: ZHANG LIANSHAN
38 granted patents·39 pending applications·299 citations·filing 2002–2023
97Inventor score
Files withJIANGSU HENGRUI MEDICINE CO31LILLY CO ELI12SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD11Shanghai hengrui pharmaceutical co ltd6GLAESNER WOLFGANG2
Top patents by PatentIndex Score
77 records- 0197US7101843B2Glucagon-like peptide-1 analogsLILLY CO ELI·Filed 2002·Granted Sep 5, 2006·149 cites·5 claims
- 0294US10905743B2Interleukin 15 protein complexJIANGSU HENGRUI MEDICINE CO·Filed 2015·Granted Feb 2, 2021·9 cites·10 claims
- 0392US10344090B2PD-1 antibody, antigen-binding fragment thereof, and medical application thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Jul 9, 2019·15 cites·27 claims
- 0491US11717559B2Interleukin 15 protein complex and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Granted Aug 8, 2023·2 cites·15 claims
- 0591US7582608B2Selective VPAC2 receptor peptide agonistsLILLY CO ELI·Filed 2006·Granted Sep 1, 2009·15 cites·3 claims
- 0690US11208484B2Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancersSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2017·Granted Dec 28, 2021·4 cites·9 claims
- 0790US10206980B2IL-15 heterodimeric protein and uses thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Feb 19, 2019·20 cites·19 claims
- 0889US11866500B2Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancersSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2021·Granted Jan 9, 2024·1 cites·17 claims
- 0989US10786567B2Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicineSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Sep 29, 2020·4 cites·18 claims
- 1088US7557183B2Polyethylene glycol linked GLP-1 compoundsLILLY CO ELI·Filed 2004·Granted Jul 7, 2009·36 cites·10 claims
- 1187US10543284B2Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Jan 28, 2020·6 cites·36 claims
- 1286US11365255B2PD-1 antibody, antigen-binding fragment thereof, and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2019·Granted Jun 21, 2022·2 cites·12 claims
- 1383US10815304B2PD-L1 antibody, antigen-binding fragment thereof and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Oct 27, 2020·3 cites·25 claims
- 1482US12435144B2Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancersSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2023·Granted Oct 7, 2025·0 cites·19 claims
- 1581US9090568B2Quinazolinediones and their useLIU DONG·Filed 2012·Granted Jul 28, 2015·6 cites·16 claims
- 1681US8183340B2GLP-1 pegylated compoundsGLAESNER WOLFGANG·Filed 2006·Granted May 22, 2012·7 cites·4 claims
- 1779US10449250B2Anti-sclerostin antibody, antigen binding fragment and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2016·Granted Oct 22, 2019·2 cites·20 claims
- 1876US7482321B2Extended glucagon-like peptide-1 analogsLILLY CO ELI·Filed 2003·Granted Jan 27, 2009·10 cites·16 claims
- 1974US10562977B2Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereofShanghai hengrui pharmaceutical co ltd·Filed 2015·Granted Feb 18, 2020·2 cites·28 claims
- 2073US9862765B2IL-17A binding agent and uses thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Jan 9, 2018·2 cites·25 claims
- 2169US11981733B2LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2021·Granted May 14, 2024·0 cites·20 claims
- 2269US11525005B2Anti-CD40 antibody, antigen binding fragment thereof and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Dec 13, 2022·1 cites·25 claims
- 2366US9050371B2PEGylated insulin lispro compoundsBEALS JOHN MICHAEL·Filed 2009·Granted Jun 9, 2015·3 cites·4 claims
- 2465US10899837B2B7-H3 antibody, antigen-binding fragment thereof and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Jan 26, 2021·0 cites·17 claims
- 2562US11155617B2LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2017·Granted Oct 26, 2021·0 cites·21 claims
- 2661US11680100B2B7-H3 antibody, antigen-binding fragment thereof and medical use thereofHANSOH SHANGHAI HEALTHTECH CO LTD·Filed 2020·Granted Jun 20, 2023·0 cites·17 claims
- 2760US10857146B2Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitorJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Dec 8, 2020·0 cites·12 claims
- 2860US7897573B2Selective VPAC2 receptor peptide agonistsLILLY CO ELI·Filed 2009·Granted Mar 1, 2011·0 cites·6 claims
- 2960US2008146500A1Selective Vpac2 Receptor Peptide AgonistsBOKVIST BENGT KRISTER·Filed 2005·Application pending·0 cites
- 3059US12227583B2Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical useJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Feb 18, 2025·0 cites·17 claims
- 3159US11780923B2PD-L1 antibody, antigen-binding fragment thereof and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2020·Granted Oct 10, 2023·0 cites·23 claims
- 3259US2021000954A1Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicineSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 3354US2022153853A1Bispecific proteinJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 3453US12240904B2Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumorsJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Mar 4, 2025·0 cites·16 claims
- 3553US2006217290A1Insulin analogs having protracted time actionKOHN WAYNE D·Filed 2004·Application pending·0 cites
- 3653US2023108572A1Method For Treating Cholesterol-Related DiseasesSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3753US2022267432A1Method for treating autoimmune disease by il-17 antagonistJIANGSU HENGRUI MEDICINE CO·Filed 2020·Application pending·0 cites
- 3853US2008318845A1Selective Vpac2 Receptor Peptide AgonistsLILLY CO ELI·Filed 2005·Application pending·0 cites
- 3952US9145451B2Glucagon superfamily peptides exhbiting G protein coupled receptor activityDIMARCHI RICHARD D·Filed 2011·Granted Sep 29, 2015·0 cites·21 claims
- 4052US2006252916A1Modified glucagon-like peptide-1 analogsLILLY CO ELI·Filed 2003·Application pending·0 cites
- 4151US10793643B2PCSK9 antibody, antigen-binding fragment thereof, and medical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2016·Granted Oct 6, 2020·0 cites·24 claims
- 4251US2009118167A1Selective Vpac2 Receptor Peptide AgonistsELI LILLY AND COMPANY PATENT D·Filed 2005·Application pending·0 cites
- 4350US2021196719A1Use of cdk4/6 inhibitor in combination with egfr inhibitor in the preparation of medicament for treating tumor diseasesJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 4449US2024016822A1Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonistSHANGHAI SHENGDI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 4549US2008194482A1Selective Apac2 Receptor Peptide AgonistsALSINA-FERNANDEZ JORGE·Filed 2006·Application pending·0 cites
- 4648US2021009706A1Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use ThereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 4748US2022025060A1Anti-cd40 antibody, antigen binding fragmentand pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 4847US12162944B2Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Dec 10, 2024·0 cites·18 claims
- 4947US2020054594A1Pharmaceutical composition containing mor agonist and kor agonist, and uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Application pending·0 cites
- 5046US2024189438A1Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicineSHANGHAI SENHUI MEDICINE CO LTD·Filed 2022·Application pending·0 cites
Showing the top 50 of 77 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →